Lunai Bioworks to Voluntarily Delist From Nasdaq; CFO and a Director Resign
LNAI is trading near its 52-week low of $0.46 (32% below the low).
Summary
Lunai Bioworks will voluntarily delist from Nasdaq after failing the $2.5M stockholders' equity rule, with trading set to suspend October 30, 2026 and no OTC market planned. The CFO and a director resigned the same day, and the company terminated its ATM and deregistered unsold shares.
Key Events · Legal and Risk Events · LNAI
-
Nasdaq Delisting Determination Received
Nasdaq notified the company on October 21, 2026 that it fails Listing Rule 5550(b)(1)'s $2,500,000 minimum stockholders' equity requirement, citing a $(9,024,946) stockholders' deficit in the fiscal 2026 10-K.
-
Voluntary Delisting, No Hearing
On October 22, 2026, the board approved voluntary withdrawal from Nasdaq listing and Section 12(b) registration and will not request a hearing, so trading suspends at the open on October 30, 2026.
-
No OTC Market Planned
The company does not intend to arrange quotation on any over-the-counter market and cannot assure any trading market will exist after the Nasdaq suspension.
-
CFO and Director Resign
CFO Nathen Fuentes and director Douglas W. Calder resigned effective October 22, 2026; no successor CFO or interim principal financial officer has been named, and the audit and compensation committees now fall below Nasdaq independence requirements.
Analysis · LNAI · Life Sciences
Rather than fight to keep its Nasdaq listing, Lunai is walking away. Nasdaq notified the company on October 21, 2026 that it fails the $2.5M minimum stockholders' equity rule — the 10-K reported a stockholders' deficit of $(9,024,946) — and because Lunai is already under a mandatory Hearings Panel Monitor, no compliance period applies. Instead of requesting a hearing by October 28, the board voted to withdraw voluntarily: trading suspends at the open on October 30, 2026, a Form 25 is expected around November 2, delisting around November 12, and a Form 15 to stop SEC reporting after that. No OTC quotation will be arranged, so holders may be left with no trading market at all. The same day brought the CFO's resignation with no successor named and a director's departure, pushing the audit and compensation committees below Nasdaq independence requirements. The ATM with Dawson James was terminated and unsold registered securities were deregistered — consistent with a company that has stopped trying to raise public equity. With less than one month of cash runway previously disclosed, the practical question is whether operations can continue at all.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 46.1% of the 280 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNAI was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.46 to $13.28. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.